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Fifty one percent severely dehydrated with Systolic BP ranged 0.0–160.0mmHg, 
median 90.0mmHg. Diastolic BP ranged 0.0-110.0 mmHg, median 60.0mmHg. Total 
fluids given ranged 0.0–13.9 L, median 5.2 L. Only 1.4% had fluid output monitored. 
Lacking health insurance (POR= 2.52, CI0.48-13.25), being referred (POR= 0.05, CI0.01-
0.21), male (POR= 0.82, CI0.32-2.16), single (POR= 0.80, CI0.26-2.46) were associated 
with late hospital presentation COnClusIOns: Instituting routine cholera death 
audits in Ghana is crucial to reducing case fatality as late presentation, inadequacy 
of assessment, rehydration, monitoring and lack of Health Insurance were main 
prevalent factors among deaths in the outbreak.
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Age RelAted CoNsultAtIoN RAtes of ClINICAlly-dIAgNosed INflueNzA 
ANd ACute ResPIRAtoRy IllNesses obseRved thRough A NetwoRk of gP 
PRACtICes ACRoss eNglANd
Wiecek W1, Amzal B1, Bakshi S1, Patel V1, Van Staa T2
1LASER Analytica, London, UK, 2University of Manchester, Manchester, UK
ObjeCtIves: Influenza infection can be recorded under number of respiratory diag-
noses when patients visit a GP. In addition, the incidence of influenza and respiratory 
infections are known to be highest in younger and elderly age groups. Our objective 
was to describe the consultation rates for eight respiratory diagnoses across four 
influenza seasons as observed through GP consultations in England. MethOds: 
Data were obtained on 775,000 respiratory related GP consultations, across four 
influenza seasons (2010-2014) from the Clinical Practitioners Research Datalink. 
Eligible patients were registered and had 12 months history with a practice at the 
start of the season. An influenza season was defined as 1 September through to 
13 April of the following year. Practice-level consultation rates for each outcome 
were determined by age (seven groups were defined) and season. A Poisson mixed 
effect model was fitted to analyse age effect with inter-practice and inter-season as 
random effects. 18 to 65 age group was the reference population. Results: Across 
all outcomes, consultation rates for influenza or respiratory illness were highest 
amongst young children, with highest rates observed for the 0 to < 2 age group, fol-
lowed by the 2 to < 4 age group. Focussing on individual diagnoses recorded during 
GP consultations, younger children were particularly at risk for upper respiratory 
tract infection and otitis media. Patients over 65 were found to be more at risk for 
pneumonia and lower respiratory tract infection. Inter-practice variation in diag-
noses rates was dominating inter-season variations for most influenza-related 
diagnoses. Biggest seasonal impact was on consultations for influenza-like-illness, 
which were particularly high during the 2010-2011 season, likely due to the H1N1 
epidemic. COnClusIOns: Our findings confirmed that children and the over 65 
population are most at risk of influenza and respiratory illness, and that incidence 
can reliably be evaluated through analysis of GP consultation rates.
INfeCtIoN – Cost studies
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heAlth eCoNomIC ImPACt of 13-vAleNt PNeumoCoCCAl CoNjugAte 
vACCINe IN fINNIsh home CARe CustomeRs ≥ 50 yeARs wIth uNdeRlyINg 
ChRoNIC medICAl CoNdItIoNs
Mankinen PT1, Soini EJ1, Laine J2, Linna M3, Åhman H2, Martikainen J1
1ESiOR Oy, Kuopio, Finland, 2Pfizer Oy, Helsinki, Finland, 3Aalto University, Espoo, Finland
ObjeCtIves: Hospital-treated pneumonias (HTP) are associated with substantial 
individual and societal burden in adults (≥ 50 years) and elderly. Moreover, adults 
e.g. with vascular, metabolic or respiratory diseases have a 3-6 times higher risk 
of HTP when compared with their healthy controls. Persons at risk are likely to 
benefit most from pneumococcal vaccinations. The 13-valent pneumococcal con-
jugate vaccine (PCV13) has showed to prevent community-acquired pneumonia and 
invasive pneumococcal disease in adults. The objective of this study was to estimate 
the expected 5-year health economic impact of targeted PCV13 compared with no 
vaccination in Finnish home care customers. MethOds: A budget impact model 
was developed to predict the impact of PCV13 vaccination in terms of costs and 
HTP events avoided at the national and municipal level. A dynamic-cohort Markov 
modelling approach and a time horizon of 5 years was used. The baseline number 
of home care customers and HTP events were gathered from Finnish national regis-
tries. The efficacy of PCV13 was estimated based on CAPITA trial. Only direct costs in 
2014 value were considered in the analysis. Results: All 105,572 Finnish home care 
customers are considered to be at moderate or high risk for HTP because of under-
lying chronic medical conditions. Vaccination of these people with PCV13 could 
provide an undiscounted net budget savings of about € 49.2 million compared with 
the current no-vaccination situation over the next 5 years. Among the risk groups 
considered, the largest absolute undiscounted net savings (€ 22.3 million) could be 
obtained by vaccinating people with heart disease, due to its high prevalence in the 
target population. COnClusIOns: In Finland, the direct immunization of home 
care customers with PCV13, is estimated to lead to substantial cost savings in the 
following 5 years after vaccination.
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budget ImPACt ANAlysIs of sofosbuvIR-bAsed RegImeNs foR the 
tReAtmeNt of hIv/hCv Co-INfeCted PAtIeNts IN NoRtheRN ItAly: the 
lIguRIA RegIoN sImulAtIoN
Cenderello G1, Artioli S2, Gaggero D1, Pasa A1, Dentone C3, Fraguglia C1, Giacomini M4, 
Giannini B4, Pastorino G5, Viscoli C6, Cassola G1, Di biagio A6
1EO Ospedali Galliera, Genoa, Italy, 2ASL-5 Spezzina, La Spezia, Italy, 3ASL-1 Imperiese, Sanremo, 
Italy, 4Genoa University, genoa, Italy, 5ASl-1 Imperiese, Sanremo, Italy, 6Genoa University, Genoa, 
Italy
ObjeCtIves: Chronic HCV is a leading cause of hospitalization and death in popu-
lations coinfected with HIV in Italy. Sofosbuvir (SOF) is a pan-genotypic drug, which 
can be used alone or combined with other agents (e.g.Simeprevir,Daclatasvir, 
Ledipasvir) as oral treatment for HCV, with different price levels. We performed 
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ePIdemIology of hePAtItIs C PAtIeNts IN ItAlIAN loCAl heAlth uNIts 
(lhus)
Degli Esposti L1, Sangiorgi D1, Buda S1, Crovato E1, Nappi C2, Lefevre C3
1CliCon S.r.l., Ravenna, Italy, 2Bristol Myers Squibb S.r.l., Roma, Italy, 3Bristol-Myers Squibb, 
Rueil-Malmaison, France
ObjeCtIves: To estimate prevalence of HCV, using data from routine practice in 
Italy MethOds: An observational retrospective cohort based on administrative 
databases (containing data from pharmacy registries, hospital discharges, outpa-
tient specialist services and laboratory tests) from a sample of six Italian LHUs was 
performed. The date of the first record related to HCV (i.e., positive HCV testing 
or medications for HCV) during the study period (July 1st, 2009 - June 31st, 2014) 
was considered as a proxy of diagnosis, and used as the index date. Patients with 
data available for at least 6 months prior to index date were followed up from the 
index date until the first of the end of the study period, date of death, or exiting the 
database Results: Overall, 228,157 health-assisted individuals living in the first 
analysed LHU (Central Italy) were considered as the starting population in the study; 
amongst them, 0.4% patients with HCV were enrolled, 56% male, age 58±16 years. 
The most prevalent genotypes were 1 (51±2%), 2 (24±2%), 3 (19±2%) and 4 (5±1%); 
other genotypes had a rate lower than 5%. In terms of co-infections, 6% patients 
were affected by HIV, 3% by HBV, 2% HCV+HBV+HIV, 26% had cirrhosis and 4% HCC. 
The majority of patients (76%) did not receive an antiviral treatment; compared to 
treated patients, they were more frequently aged > 65 years (44% compared to 14% 
in treated patients), females (46%, vs 40%), under ongoing substance/alcohol abuse 
(7% vs 4%). Moreover, 30% of untreated patients had cirrhosis and 5% HCC. Results 
from other LHUs will be available at ISPOR-EU COnClusIOns: This observational 
study showed that 70% of enrolled HCV patients has genotype 1 and 3, and only 
a small proportion of patients with HCV received antiviral therapy. Future analy-
ses should investigate relationships between patients’ characteristics, therapeutic 
choices and outcomes
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ePIdemIologICAl dAtA used IN RotAvIRus vACCINAtIoN  
Cost-effeCtIveNess ANAlysIs IN euRoPe: A lIteRAtuRe RevIew  
uPdAte
Li X1, Theodorou E2, Standaert B1
1GSK Vaccines, Wavre, Belgium, 2UK PHARMA, GSK Vaccines UK, MIDDLESEX, UK
ObjeCtIves: Rotavirus gastroenteritis (RVGE) is the leading cause of severe diarrhea 
in children under 5 years of age. Two rotavirus vaccines are licensed to prevent these 
infections. More than hundred economic evaluations have been published on rota-
virus vaccination since 2006 and their results largely vary. An update of a literature 
view was conducted aiming to assess whether differences in the epidemiologi-
cal data used in European evaluations could explain the differences in the results 
obtained. MethOds: A literature review was conducted to retrieve articles reporting 
the cost-effectiveness of rotavirus vaccination in Europe based on criteria used in 
a previously published review (limited to 2001-2011 studies, this update extended 
the search to May 2015), focusing on epidemiological data. The following annual 
incidence RVGE-related data were extracted from the retrieved articles and grouped 
by countries: community-acquired hospitalisation (CAH), emergency department 
(ED) visits, outpatient visits (including general practitioner or paediatrician) and 
RVGE events (including no medical visits). Variations within countries were also 
calculated as the ratio between the maximum and minimum value. Results: 32 
publications (24 manuscripts and 8 conference abstracts) from 13 European coun-
tries were retrieved. The European average (minimum and maximum reported 
value) annual rates were CAH 0.57% (0.09% Portugal; 1.43% Albania), ED visits 1.13% 
(0.22% Portugal; 2.40% France), outpatient visits 3.11% (0.56% Netherlands; 7.17% 
Romania) and RVGE events 9.05% (5.63% Germany; 20.01% Spain). For the countries 
with multiple publications, rates of CAH and outpatient visits showed large variation 
(CAH: France 2.82; outpatient: Ireland 5.78). RVGE rates were generally consistent 
except for United Kingdom (1.93) and Germany (2.50). For ED visit rates the largest 
variability was observed in France (3.16). COnClusIOns: The RGVE disease bur-
den used as input in economic evaluation varies among the studies in the same 
country and across Europe. This may explain the difference in the cost-effective 
results reported.
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CholeRA deAth AudIt IN ghANA: A medICAl ReCoRd RevIew of the 2014 
outbReAk
Davies-Teye B1, Nyarko K2, Brown-Davies C2, Bredu M2, Eleeza J2, Vanotoo La2
1Ghana Health Service and Drifney Consult Ltd, Accra, Ghana, 2Ghana Health Service, Accra, 
Ghana
ObjeCtIves: Ghana has documented recurrent Cholera outbreaks (Davies-Teye, 
2014); the worst ever in 2014 had high case, death incidence and yet does not rou-
tinely audit these deaths. Auditing the deaths would improve healthcare quality 
delivered to clients This study aimed at developing standardized Cholera Death 
audit tool, describe the deaths and identify prevalent factors that contributed to 
deaths. MethOds: Standardized cholera death audit tool was developed. Census 
of cholera deaths from June – December 2014 in Greater Accra Region made. Medical 
records, surveillance data of deaths from treatment centers reviewed with the devel-
oped audit tool. Data abstracted included socio-demographic, clinical, patient moni-
toring. Data managed in Epi info7. Descriptive, bivariate analysis made and Prevalent 
Odds Ratio (95% Confidence Interval) determined to identify prevalent factors asso-
ciated with deaths. Results: The region documented 20,199 (Attack rate 432 per 
100,000 populations) cholera cases with 121 deaths (CFR 0.60%). La Nkwantanang-
Madina and Ladade Kotopon were most affected with Attack rates above 600 per 
100,000 populations. Ada East, Ashaiman and LEKMA had case fatalities above 0.9%. 
Ages ranged 1–82 years, mean 41.0 ±17, median 39.0, mode 24.0 years. Males consti-
tuted 65.7% and 90.9% did not have health insurance. Duration of home stay ranged 
0-5days. Nineteen percent were dead on arrival and 20.2% within 4hours of arrival. 
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Arabia MethOds: Retrospective cohort study for patients admitted to surgi-
cal wards at a tertiary care center in Jeddah, Saudi Arabia over 3 months. Three 
broad spectrum antibiotics were targeted; piperacillin/tazobactam, imipenem, 
and meropenem. De-escalation delay was measured in days from the time of 
getting the culture identification and susceptibility until narrowing the antimi-
crobial therapy to target the identified organism. The cost impact was measured 
by multiplying the period that patients were on broad spectrum antibiotics after 
the final identification and susceptibility of microorganism by the cost of broad-
spectrum antibiotics per day. Results: One hundred sixty-three patients received 
broad spectrum antibiotics over 3 months on surgical wards at our institution. 
Sixty four out 163 patient (39.2%) had identified organism and susceptibility for 
other antibiotics. Thirty one patients (48.4%) had de-escalation of antimicrobial 
therapy within 24 hrs of culture identification and susceptibility result. Thirty 
three patients (51.6%) had a delay in their broad spectrum antibiotics therapy 
de-esclation despite getting the culture identification and susceptibility. The total 
delay of broad spectrum antibiotics and cost impact were as follow: piperacillin/
tazobactam 267 days (3,920 USD); imipenem 5 days (230 USD); meropenem 110 
days (9,925 USD). COnClusIOns: the delay of broad spectrum antibiotics de-
escalation on surgical wards at our hospital has resulted in a cost impact of 14,075 
USD over 3 months period. Pharmacy intervention program on surgical wards to 
enforce the de-escalation process is needed.
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ChAlleNges IN eCoNomIC evAluAtIoN of ANtIbIotICs IN heAlth-CARe 
ACquIRed INfeCtIoNs: A tARgeted RevIew
Chapman R1, Kongnakorn T2
1Evidera, London, UK, 2Evidera, Bangkok, Thailand
ObjeCtIves: Health-care acquired infections (HCAIs) and resulting antibiotic treat-
ments have been raising global concerns. HCAIs represent a substantial economic 
and humanistic burden with increasing costs, morbidity and mortality. Concerns 
around antibiotic use include resistance and lack of new products to market. The 
latter is related to difficulty in gaining approval, potential lack of profitability, 
complicated market assess, and difficulty in demonstrating value. Methods used 
for economic evaluations may contribute to the difficulty in assessing antibiot-
ics. Our objective was to review published economic evaluations of antibiotics in 
HCAIs and to summarize currently used methods and challenges in assessing 
cost-effectiveness. MethOds: We conducted a MEDLINE search for model-based, 
health economic evaluations of antibiotics in the six most prevalent HCAIs in the 
UK (respiratory tract, urinary tract, surgical site, clinical sepsis, gastrointestinal and 
bloodstream infections). Original, English language studies were included. Among 
others, analysis type, model structure, perspective, time horizon and outcomes were 
extracted. Results: We identified 126 papers, of which 19 met the inclusion criteria. 
These included 13 cost-effectiveness, four cost-consequence, one cost-minimization 
and one cost-benefit analyses. Of the models 12 were decision trees/decision mod-
els, three cost-calculators, one Markov model and one discrete even simulation. 2 
papers did not report sufficient methodology. Time horizons were mainly the length 
of an infection. Main outcomes were cost-per cure, cost-per patient treated, cost-
per QALY and total cost saving. Economic models tend not to account for changes 
in prevalence of resistance, and additional potential benefits such as preventing 
transmission of resistance. COnClusIOns: Most identified economic evaluations 
were simplistic, using cost-effectiveness approach through a simple decision tree, 
over short time-horizon, with payer perspective. This limits the flexibility of the 
evaluations to account for benefits of antibiotics in addressing burden of HCAIs and 
the current global concerns, contributing to the difficulty of assessing economic 
benefit of antibiotics.
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A systemAtIC lIteRAtuRe RevIew of the eCoNomIC ImPlICAtIoNs of 
ACute bACteRIAl skIN ANd skIN stRuCtuRe INfeCtIoNs (AbsssIs)
Degener F1, Ivanescu C2, Casamayor M3, Postma M1
1University of Groningen, Groningen, The Netherlands, 2Quintiles Advisory Services, Hoofddorp, 
The Netherlands, 3Quintiles, Barcelona, Spain
ObjeCtIves: During the years, acute bacterial skin and skin structure infections 
(ABSSSIs) have seen an increase in incidence in many parts of the western world. 
Additionally, the treatment of ABSSSIs, generally consisting of surgical debride-
ment or drainage and empiric antibiotics in the hospital, can be further compli-
cated by emerging multi drug resistant bacteria, most notably methicillin-resistant 
Staphylococcus aureus (MRSA). As the incidence rates increase alongside with ris-
ing antibiotic resistance, ABSSSIs are becoming a significant burden for healthcare 
systems. This study aims to collect evidence on the healthcare resource utilization 
of ABSSSI and the economic implications of different treatment modalities for 
the management of these diseases. MethOds: A systematic literature search in 
MEDLINE, Cochane and ISPOR abstract databases with predefined inclusion criteria 
and subsequent quality assessment was performed. Results: The search identi-
fied 1,799 unique publications of which 26 contained relevant economic data on 
ABSSSIs treatment and were therefore included in this manuscript. There were six 
healthcare resource utilization studies, 11 cost analyses, three cost-minimization 
and six cost-effectiveness analyses, of which only a single study reported quality 
adjusted life years. Vancomycin was evaluated in most studies (21), followed by lin-
ezolid (15), daptomycin (8) and others (7). COnClusIOns: This review provides an 
in-depth overview of the economic implications of current ABSSSI management. 
Major cost drivers of ABSSSI treatment were length of hospital stay and the overall 
cost associated with frequent intravenous antibiotics administration. While most 
studies (20) applied a hospital perspective, there was a substantial disparity on the 
specific costs in- or excluded in the analysis, and on the unit prices. This led to 
significant variations of the final cost outcomes. Notably, over 10-fold differences 
were found. The overall quality and comparability of the literature reviewed was 
sub-optimal, elevating the need for more high-quality and reproducible economic 
evaluations in the area of ABSSSIs.
a 5 year-horizon budget impact analysis of SOF-based regimens for the manage-
ment of HIV/HCV-coinfected patients MethOds: This prospective study involved 
4 Italian Infectious Diseases Departments in the Liguria Region. A total of 1.005 
coinfected patients (30% cirrhotics) in any stage of their hepatic disease stages 
was considered (F0-F4, cirrhosis,transplanted,HCC). Disease stage costs per patient 
were collected, taking into account the rate of expected disease progression in 
absence of treatment and the rate of Sustained Virological Response (SVR)with 
SOF-based regimens. The success rate for SOF-based Regimens was estimated 
based on literature data, whilst the liver disease progression in a such short period 
was evaluted according to expert opinion. Drugs prices used in the calculation 
were those paid by the Italian Health Service. Two scenarios were compared: ”no 
treatment” versus b) SOF-based treatment. Data were analyzed from the Regional 
Health Service standpoint Results: Over the next 5 years, the total expense in 
a “no treatment” scenario (base case) should approximate 54 M Euros. Assuming 
an SVR success rate of 90%, average SOF-based regimens price higher than € 
50.000 costs more than € 55 millions, resulting not convenient. At the average 
price of 15.000 € per patient, the total expense in the SOF-based scenario should 
approach 20 MEuros , i.e. more than 60% lower than in the “no-treatment” sce-
nario. COnClusIOns: The results suggest that at the average price of € 15.000 
per patient over the next 5 years, the use of SOF should allow saving half of the 
economic resources needed to manage the HIV/HCV disease population.
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A dyNAmIC model to estImAte the budget ImPACt of A NeumoCoCCAl 
vACCINAtIoN PRogRAm IN sPAIN
Varona JL1, Lorente MR1, Antoñanzas F1, Rejas J2
1Universidad de La Rioja, Logroño, Spain, 2Pfizer, Alcobendas, Spain
ObjeCtIves: The purpose of this study is to estimate the 5-year budget impact 
of a pneumococcal vaccination program of population aged 65-year-old in 
Spain. MethOds: A dynamic model based on differential equations was built for 
the conceptualization of the disease and the parameters were populated with the 
vaccine efficacy data coming from the CAPITA clinical trial of the 13-valent pneu-
mococcal conjugate vaccine (PCV13). If S stands for susceptible, I for infective, V 
shows the number of individuals who are effectively vaccinated at each time and 
t is the time variable and the parameters beta and gamma show the transmission 
and natural recovery coefficients respectively, the differential equation of the model 
is: dS(t)/dt= -β *I(t)*S(t)+γ *I(t)-V(t) and dI(t)/dt= +β *I(t)*S(t)-γ *I(t). Program duration was 
fixed to 5 years, and every year the 65-year cohort would be vaccinated (coverage 
of 49.3%). Economic parameters included hospital costs of treating pneumonias, 
meningitis, bacteremia, and empyema as well as the outpatient costs of treating 
pneumonia in the community (41.5% of the cases). Costs sources were official data-
bases for hospitalizations and vaccine, and a local study for outpatient costs of 
pneumonia. Mortality rates related to pneumococcal infections reported in the UK 
are applied to the Spanish case. Results: In 5 years-period with a 65 year old cohort 
of 513,000 people, the vaccination program is expected to avoid about 35,700 cases 
of pneumococcal disease (the majority of them otherwise causing pneumonia), 
and about 1,419 related deaths. Vaccination costs of 59.5 million euros would be 
completely offset by medical cost reduction of 124 million euros, yielding to a net 
saving of 64.5 million euros. COnClusIOns: PCV13 vaccination targeting the cohort 
of 65 year-old Spanish adults is expected to result in net savings for the health care 
system in addition to significant cases of pneumonia avoided and related health 
improvements for the patients.
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budget ImPACt ANAlysIs of the use of dAClAtAsvIR foR the tReAtmeNt 
of hePAtItIs C vIRus (hCv) geNotyPes 3, IN the ItAlIAN settINg
Restelli U1, Bonfanti M1, Alberti A2, Lazzarin A3, Nappi C4, Croce D1
1LIUC University, Castellanza, Italy, 2Università degli studi di Padova, Padova, Italy, 3University 
Vita-Salute San Raffaele, Milan, Italy, 4Bristol Myers Squibb S.r.l., Rome, Italy
ObjeCtIves: New HCV antiviral treatments showed higher effectiveness (sustained 
virologic response - SVR) compared with that of available drugs. Due to the high cost 
of such treatments and in absence of scientific evidence on their economic impact 
on the Italian National Health Service (NHS), it is crucial to investigate the sustain-
ability of their use in the Italian setting. The study aimed at evaluating the budget 
impact on the Italian NHS of the use of Daclatasvir for HCV treatment. MethOds: 
An analytical decision model was implemented with a five year time horizon. Two 
scenarios were structured considering the market shares of HCV treatments (expert 
opinion) with or without the use of Daclatasvir. The target population (HCV genotype 
3 infected patients) was estimated based on literature data. Patients enter the model 
in fibrosis stage 3 and 4 and may evolve in an SVR state (based on effectiveness 
data), decompensated cirrhosis, HCC, liver transplant or death. The costs considered 
in the analysis were those of antiviral treatment, adverse events management and 
health state costs. Results: The use of Daclatasvir, in comparison with the scenario 
without Daclatasvir, would lead to an increase of costs for the Italian NHS of 21.31 
million euros in year 1, 21.33 million euros in year 2, 23.36 million euros in year 
3, 23.26 million euros in year 4 and 17.20 million euros in year 5. COnClusIOns: 
Daclatasvir would lead to an increase of healthcare costs for the treatment of geno-
type 3 HCV infected patients in the first three years, followed by a reduction of the 
cost’s increase in years 4 and 5 (-0.44% in year 4 compared with year 3, and -26.0% in 
year 5 compared with year 4), thanks to the management of better health conditions, 
due to the higher effectiveness of Daclatasvir based therapies than the comparators.
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Cost ImPACt of the delAy of bRoAd-sPeCtRum ANtImICRobIAl AgeNts 
de-esClAtIoN oN suRgICAl wARds
Aseeri M, Youssif E, Khoshhal S
King Abdul Aziz Medical City, Jeddah, Saudi Arabia
ObjeCtIves: To measure the cost impact of the delay of broad spectrum antibi-
otics de-escalation on surgical wards at a tertiary care center in Jeddah, Saudi 
